ZIMMER BIOMET HOLDINGS, INC. (NYSE:ZBH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On April10, 2018, Katarzyna Mazur-Hofsaess, M.D., Ph.D., President, Europe, Middle East and Africa (“EMEA”) of Zimmer Biomet Holdings, Inc. (the “Company”), informed the Company that she will resign her officer positions with the Company and its affiliates. Dr.Mazur-Hofsaess will continue on with her full EMEA leadership responsibilities through May31, 2018 and will be available for an additional transition period for a number of months thereafter.
About ZIMMER BIOMET HOLDINGS, INC. (NYSE:ZBH)
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consists of the United States and includes other North, Central and South American markets; EMEA, consists of Europe and includes the Middle East and African markets, and Asia Pacific, consists of Japan and includes other Asian and Pacific markets. Its four product category segments include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic, and Dental.
